Search

Your search keyword '"Zon, Rebecca L."' showing total 27 results
Start Over Author "Zon, Rebecca L."
27 results on '"Zon, Rebecca L."'

3. The CoVID‐TE risk assessment model for venous thromboembolism in hospitalized patients with cancer and COVID‐19

Author

Li, Ang, Kuderer, Nicole M, Hsu, Chih‐Yuan, Shyr, Yu, Warner, Jeremy L, Shah, Dimpy P, Kumar, Vaibhav, Shah, Surbhi, Kulkarni, Amit A, Fu, Julie, Gulati, Shuchi, Zon, Rebecca L, Li, Monica, Desai, Aakash, Egan, Pamela C, Bakouny, Ziad, Devendra, KC, Hwang, Clara, Akpan, Imo J, McKay, Rana R, Girard, Jennifer, Schmidt, Andrew L, Halmos, Balazs, Thompson, Michael A, Patel, Jaymin M, Pennell, Nathan A, Peters, Solange, Elshoury, Amro, de Lima Lopes, Gilbero, Stover, Daniel G, Grivas, Petros, Rini, Brian I, Painter, Corrie A, Mishra, Sanjay, Connors, Jean M, Lyman, Gary H, Rosovsky, Rachel P, and consortium, the CCC19

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Clinical Research, Prevention, Hematology, Cancer, COVID-19, Cohort Studies, Humans, Neoplasms, Risk Assessment, SARS-CoV-2, Venous Thromboembolism, clinical decision rules, thrombosis, venous thromboembolism, CCC19 consortium, Cardiorespiratory Medicine and Haematology, Clinical Sciences, Cardiovascular System & Hematology, Cardiovascular medicine and haematology, Clinical sciences
Abstract

BackgroundHospitalized patients with COVID-19 have increased risks of venous (VTE) and arterial thromboembolism (ATE). Active cancer diagnosis and treatment are well-known risk factors; however, a risk assessment model (RAM) for VTE in patients with both cancer and COVID-19 is lacking.ObjectivesTo assess the incidence of and risk factors for thrombosis in hospitalized patients with cancer and COVID-19.MethodsAmong patients with cancer in the COVID-19 and Cancer Consortium registry (CCC19) cohort study, we assessed the incidence of VTE and ATE within 90 days of COVID-19-associated hospitalization. A multivariable logistic regression model specifically for VTE was built using a priori determined clinical risk factors. A simplified RAM was derived and internally validated using bootstrap.ResultsFrom March 17, 2020 to November 30, 2020, 2804 hospitalized patients were analyzed. The incidence of VTE and ATE was 7.6% and 3.9%, respectively. The incidence of VTE, but not ATE, was higher in patients receiving recent anti-cancer therapy. A simplified RAM for VTE was derived and named CoVID-TE (Cancer subtype high to very-high risk by original Khorana score +1, VTE history +2, ICU admission +2, D-dimer elevation +1, recent systemic anti-cancer Therapy +1, and non-Hispanic Ethnicity +1). The RAM stratified patients into two cohorts (low-risk, 0-2 points, n = 1423 vs. high-risk, 3+ points, n = 1034) where VTE occurred in 4.1% low-risk and 11.3% high-risk patients (c statistic 0.67, 95% confidence interval 0.63-0.71). The RAM performed similarly well in subgroups of patients not on anticoagulant prior to admission and moderately ill patients not requiring direct ICU admission.ConclusionsHospitalized patients with cancer and COVID-19 have elevated thrombotic risks. The CoVID-TE RAM for VTE prediction may help real-time data-driven decisions in this vulnerable population.

Published
2021

7. Clinical efficacy and safety of chimeric antigen receptor T‐cell therapy for mantle cell lymphoma with secondary central nervous system involvement

Author

Ryan, Christine E., primary, Zon, Rebecca L., additional, Redd, Robert, additional, Fisher, David C., additional, Shouval, Roni, additional, Kumar, Anita, additional, Crombie, Jennifer L., additional, Sadrzadeh, Hossein, additional, Kim, Austin I., additional, Nayak, Lakshmi, additional, Chukwueke, Ugonma N., additional, Jacobson, Caron A., additional, Frigault, Matthew J., additional, Palomba, M. Lia, additional, Armand, Philippe, additional, Epstein‐Peterson, Zachary, additional, and Merryman, Reid W., additional

Published
2023
Full Text
View/download PDF

10. Thrombosis-Related Loss of Arterial Lines in the First Wave of COVID-19 and Non–COVID-19 Intensive Care Unit Patients

Author

Zon, Rebecca L., primary, Merz, Lauren E., additional, Fields, Kara G., additional, Grandoni, Jessica, additional, Stuart, Jessica C., additional, Occhiogrosso, Rachel H., additional, Li, Linda, additional, Baron, Rebecca M., additional, Fredenburgh, Laura E., additional, Woolley, Ann E., additional, Connors, Jean M., additional, and Frendl, Gyorgy, additional

Published
2022
Full Text
View/download PDF

13. Intermediate versus standard dose heparin prophylaxis in COVID-19 ICU patients: A propensity score-matched analysis

Author

Moll, Matthew, primary, Zon, Rebecca L., additional, Sylvester, Katelyn W., additional, Rimsans, Jessica, additional, Chen, Evan C., additional, Ghosh, Auyon J., additional, Abston, Eric, additional, Kim, Andy, additional, Rutherford, Henry, additional, Mitre, Xhoi, additional, Hakim, Aaron, additional, Connell, Nathan T., additional, Battinelli, Elisabeth, additional, Fredenburgh, Laura E., additional, Baron, Rebecca M., additional, Hobbs, Brian D., additional, Cho, Michael H., additional, Mittleman, Murray A., additional, Woolley, Ann E., additional, and Connors, Jean M., additional

Published
2021
Full Text
View/download PDF

14. A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance

Author

Abidi, Maheen, primary, Aboulafia, David M., additional, Accordino, Melissa K., additional, Acoba, Jared D., additional, Ahluwalia, Manmeet S., additional, Ahmad, Syed A., additional, Ajmera, Archana, additional, Alimohamed, Saif I., additional, Altman, Jessica, additional, Angevine, Anne H., additional, Bakouny, Ziad, additional, Bar, Michael H., additional, Bardia, Aditya, additional, Barnholtz-Sloan, Jill S., additional, Barrow McCollough, Briana, additional, Bashir, Babar, additional, Batist, Gerald, additional, Bekaii-Saab, Tanios S., additional, Berg, Stephanie, additional, Bernicker, Eric H., additional, Bhutani, Divaya, additional, Bilen, Mehmet A., additional, Bindal, Poorva, additional, Bishnoi, Rohit, additional, Blau, Sibel, additional, Bohachek, Pamela, additional, Boland, Genevieve, additional, Bonnen, Mark, additional, Bouchard, Gabrielle, additional, Bouganim, Nathaniel, additional, Bowles, Daniel W., additional, Busser, Fiona J., additional, Butt, Omar, additional, Cabal, Angelo, additional, Cabalona, Wilhelmina D., additional, Cabebe, Elwyn C., additional, Caimi, Paolo, additional, Campian, Jian L., additional, Carducci, Theresa M., additional, Chen, James L., additional, Cheng, Alex, additional, Chism, David D., additional, Choueiri, Toni K., additional, Clark, Melanie J., additional, Clement, Jessica M., additional, Connors, Jean M., additional, Cook, Erin, additional, Curran, Catherine R., additional, Daher, Ahmad, additional, Dailey, Mark E., additional, Davis, Elizabeth J., additional, Dawsey, Scott J., additional, Deeken, John F., additional, Del Prete, Salvatore A., additional, Demetri, George D., additional, Desai, Aakash, additional, Doroshow, Deborah B., additional, Durbin, Eric B., additional, Egan, Pamela C., additional, Elias, Rawad, additional, Elkrief, Arielle, additional, Elms, Destry J., additional, Elshoury, Amro, additional, Faller, Bryan, additional, Farmakiotis, Dimitrios, additional, Fecher, Leslie A., additional, Feldman, Lawrence E., additional, Ferrario, Cristiano, additional, Fiala, Mark A., additional, Flora, Daniel B., additional, French, Benjamin, additional, Friese, Christopher R., additional, Fu, Julie C., additional, Gadgeel, Shirish M., additional, Gainor, Justin, additional, Galsky, Matthew D., additional, Gantt, Gerald, additional, Garcia, Jorge A., additional, Gartrell, Benjamin A., additional, Gatti-Mays, Margaret E., additional, Gill, David M., additional, Gillaspie, Erin A., additional, Giordano, Antonio, additional, Glace, (Mary) Grace, additional, Glover, Michael J., additional, Goel, Sanjay, additional, Graber, Jerome J., additional, Griffiths, Elizabeth A., additional, Grivas, Petros, additional, Grover, Punita, additional, Gulati, Anthony P., additional, Gulati, Shuchi, additional, Gupta, Shilpa, additional, Gurley, Michael, additional, Hafez, Navid, additional, Halabi, Susan, additional, Halfdanarson, Thorvardur R., additional, Halmos, Balazs, additional, Hausrath, Daniel J., additional, Hawley, Jessica E., additional, Hennessy, Cassandra, additional, Herbst, Roy S., additional, Hershman, Dawn L., additional, Hoppenot, Claire, additional, Hoskins, Kent F., additional, Hoyo-Ulloa, Irma, additional, Hsu, Emily, additional, Hsu, Chih-Yuan, additional, Hwang, Clara, additional, Islam, Jessica Yasmine, additional, Jabbour, Salma K., additional, Jani, Chinmay, additional, Jha, Alokkumar, additional, Jhawar, Sachin R., additional, Johnson, Douglas B., additional, Joshi, Monika, additional, Kasi, Anup, additional, Kelleher, Kaitlin, additional, Kennecke, Hagen F., additional, Khaki, Ali Raza, additional, Khan, Hina, additional, Khan, Mahir, additional, Kharofa, Jordan, additional, Kloecker, Goetz, additional, Knoble, Jeanna L., additional, Kulkarni, Amit A., additional, Kumar, Vaibhav, additional, Lammers, Philip E., additional, Leighton, John C., additional, Lemmon, Christopher A., additional, Lewis, Mark A., additional, Li, Ang, additional, Li, Xuanyi, additional, Liu, Stephen V., additional, Lo, K.M., additional, Loaiza-Bonilla, Arturo, additional, Logan, Barbara B., additional, Loggers, Elizabeth T., additional, de Lima Lopes, Gilberto, additional, Loree, Jonathan M., additional, LoRusso, Patricia, additional, Low, Clarke A., additional, Lustberg, Maryam B., additional, Lyman, Gary H., additional, Lynch, Ryan C., additional, Madhavan, Subha, additional, Mahadevan, Daruka, additional, Mahmood, Sana Z., additional, Mansoor, Abdul-Hai, additional, Marcum, Michelle, additional, Markham, Merry-Jennifer, additional, Mashru, Sandeep H., additional, Masters, Tyler, additional, Mavromatis, Blanche H., additional, McKay, Rana R., additional, McNair, Christopher, additional, McWeeney, Shannon, additional, Menendez, Alvaro G., additional, Menon, Harry, additional, Mesa, Ruben A., additional, Mico, Vasil, additional, Miller, Chaim, additional, Mishra, Sanjay, additional, Monahan, Ryan S., additional, Morgans, Alicia K., additional, Mulcahy, Mary F., additional, Mundt, Daniel, additional, Mushtaq, Sarah, additional, Nagaraj, Gayathri, additional, Nagle, Sarah, additional, Nakasone, Elizabeth S., additional, Nakayama, John M., additional, Nelson, Heather H., additional, Nemecek, Eneida R., additional, Nguyen, Ryan H., additional, Nizam, Amanda, additional, Nohria, Anju, additional, Nuzzo, Pier Vitale, additional, Ohri, Nitin, additional, Olszewski, Adam J., additional, Owenby, Susie, additional, Painter, Corrie A., additional, Palmer, Joshua D., additional, Panagiotou, Orestis A., additional, Park, Cathleen, additional, Pasquinelli, Mary M., additional, Patel, Jaymin M., additional, Patel, Kanishka G., additional, Peddi, Prakash, additional, Pennell, Nathan A., additional, Peters, Solange, additional, Pilar, Christine, additional, Pillainayagam, Clement, additional, Puc, Matthew, additional, Ramirez, Amelie G., additional, Rathmann, Joerg, additional, Ravindranathan, Deepak, additional, Reid, Sonya A., additional, Reuben, Daniel Y., additional, Revankar, Sanjay G., additional, Reynolds, Kerry L., additional, Rho, Young Soo, additional, Rhodes, Terence D., additional, Rice, Robert L., additional, Riess, Jonathan, additional, Rini, Brian I., additional, Rink, Cameron, additional, Rosen, Lane R., additional, Rosenstein, Lori J., additional, Rosovsky, Rachel P., additional, Routy, Bertrand, additional, Rovito, Marc A., additional, Rubinstein, Samuel M., additional, Saif, M. Wasif, additional, Salazar, Mary, additional, Santos Dutra, Miriam, additional, Schapira, Lidia, additional, Schmidt, Andrew L., additional, Schroeder, Brett A., additional, Schwartz, Gary K., additional, Schwartz, Candice, additional, Schweizer, Michael T., additional, Serrano, Oscar K., additional, Shafer, Danielle A., additional, Shah, Pankil K., additional, Shah, Dimpy, additional, Shah, Mansi R., additional, Shah, Sumit A., additional, Shah, Chintan, additional, Shaw, Grace, additional, Shaya, Justin A., additional, Shyr, Yu, additional, Slosky, David A., additional, Smits, Melissa, additional, Solorzano, Carmen C., additional, Stauffer, Karen, additional, Stockerl-Goldstein, Keith E., additional, Stover, Daniel G., additional, Stratton, Jamie, additional, Stratton, Catherine, additional, Streckfuss, Mitrianna, additional, Subbiah, Suki, additional, Tachiki, Lisa, additional, Tadesse, Eyob, additional, Thompson, Michael A., additional, Topaloglu, Umit, additional, Tucker, Matthew D., additional, Van Allen, Eliezer M., additional, Van Loon, Susan, additional, Vega-Luna, Karen, additional, Venepalli, Neeta K., additional, Verma, Amit, additional, Vikas, Praveen, additional, Vinayak, Shaveta, additional, Vinh, Donald C., additional, Wagner, Michael J., additional, Wall, Sarah, additional, Wang, Lucy L., additional, Warner, Jeremy L., additional, Wehbe, Firas H., additional, Weinstein, Paul L., additional, Weiss, Matthias, additional, Weissmann, Lisa B., additional, Wildes, Tanya M., additional, Williams, Nicole, additional, Wise-Draper, Trisha M., additional, Wood, William A., additional, Wu, Julie Tsu-Yu, additional, Wulff-Burchfield, Elizabeth M., additional, Xie, Zhuoer, additional, Xu, Wenxin, additional, Yeh, Albert C., additional, Yu, Irene S., additional, Yu, Peter Paul, additional, Zacks, Rosemary, additional, Zaman, Qamar Ul, additional, Zaren, Howard, additional, Zhang, Tian, additional, Zhou, Alice Y., additional, Zhu, Huili, additional, Zon, Rebecca L., additional, and Zubiri, Leyre, additional

Published
2020
Full Text
View/download PDF

15. VTE in ICU Patients With COVID-19

Author

Moll, Matthew, primary, Zon, Rebecca L., additional, Sylvester, Katelyn W., additional, Chen, Evan C., additional, Cheng, Vivien, additional, Connell, Nathan T., additional, Fredenburgh, Laura E., additional, Baron, Rebecca M., additional, Cho, Michael H., additional, Woolley, Ann E., additional, and Connors, Jean M., additional

Published
2020
Full Text
View/download PDF

17. How I manage inpatient consultations for quantitative neutrophil abnormalities in adults

Author

Zon, Rebecca L. and Berliner, Nancy

Abstract

Neutrophilia and neutropenia commonly lead to inpatient hematology consultation. Quantitative neutrophil abnormalities have a broad differential and include diagnoses that are important to recognize because they may be associated with increased mortality. Neutrophilia can reflect etiologies such as infection, medications, inflammation, splenectomy, and congenital disorders. Neutropenia can arise from infection, medications, autoimmune destruction, sequestration, nutritional deficiency, malignancy, and congenital neutropenia syndromes. In the evaluation of all abnormalities of neutrophil number, the timing of the change, and the patient’s historical neutrophil count are crucial.

Published
2024
Full Text
View/download PDF

18. Treatment Outcomes and Prognostic Factors with Lenalidomide, Bortezomib, and Dexamethasone (RVd) Alone Versus Rvd Plus Autologous Stem Cell Transplantation (ASCT) in African American (AA) Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the Determination Phase 3 Trial

Author

Houde, Christiane A., Khan, Abdullah, Jacobus, Susanna J., Hassoun, Hani, Anderson, Larry D., Merz, Lauren E., Zon, Rebecca L., Efebera, Yvonne, Buck, Tondre, Innis-Shelton, Racquel D., Hartley-Brown, Monique A, Lonial, Sagar, Campagnaro, Erica L., Voorhees, Peter M., Orlowski, Robert Z., Libby, Edward, Hurd, David Duane, Costello, Caitlin L., Raje, Noopur S., Medvedova, Eva, McCarthy, Philip L., Milner, Carter P., Gasparetto, Cristina, Agha, Mounzer E, Gowin, Krisstina, Kamble, Rammurti T., Jagannath, Sundar, Nathwani, Nitya, Alsina, Melissa, Giralt, Sergio A., Laubach, Jacob P., Nadeem, Omar, Ghobrial, Irene M., Mo, Clifton C., Samur, Mehmet K., Anderson, Kenneth C., Munshi, Nikhil C, and Richardson, Paul G.

Abstract

Background

Published
2023
Full Text
View/download PDF

21. Induced pluripotent stem cells with a pathological mitochondrial DNA deletion

Author

Cherry, Anne B. C., Gagne, Katelyn E., McLoughlin, Erin M., Baccei, Anna, Gorman, Bryan, Hartung, Odelya, Miller, Justine D., Zhang, Jin, Zon, Rebecca L., Ince, Tan A., Neufeld, Ellis J., Lerou, Paul H., Fleming, Mark D., Daley, George Q., and Agarwal, Suneet

Subjects
Mitochondrial Diseases, Acyl-CoA Dehydrogenase, Long-Chain, Induced Pluripotent Stem Cells, Cell Differentiation, Fibroblasts, Hematopoietic Stem Cells, DNA, Mitochondrial, Article, Lipid Metabolism, Inborn Errors, Anemia, Sideroblastic, Cell Line, Muscular Diseases, Child, Preschool, Congenital Bone Marrow Failure Syndromes, Humans, Female, Sequence Deletion
Abstract

In congenital mitochondrial DNA (mtDNA) disorders, a mixture of normal and mutated mtDNA (termed heteroplasmy) exists at varying levels in different tissues, which determines the severity and phenotypic expression of disease. Pearson marrow pancreas syndrome (PS) is a congenital bone marrow failure disorder caused by heteroplasmic deletions in mtDNA. The cause of the hematopoietic failure in PS is unknown, and adequate cellular and animal models are lacking. Induced pluripotent stem (iPS) cells are particularly amenable for studying mtDNA disorders, as cytoplasmic genetic material is retained during direct reprogramming. Here, we derive and characterize iPS cells from a patient with PS. Taking advantage of the tendency for heteroplasmy to change with cell passage, we isolated isogenic PS-iPS cells without detectable levels of deleted mtDNA. We found that PS-iPS cells carrying a high burden of deleted mtDNA displayed differences in growth, mitochondrial function, and hematopoietic phenotype when differentiated in vitro, compared to isogenic iPS cells without deleted mtDNA. Our results demonstrate that reprogramming somatic cells from patients with mtDNA disorders can yield pluripotent stem cells with varying burdens of heteroplasmy that might be useful in the study and treatment of mitochondrial diseases.

Published
2013

22. Pearson marrow pancreas syndrome in patients suspected to have Diamond-Blackfan anemia

Author

Gagne, Katelyn E., primary, Ghazvinian, Roxanne, additional, Yuan, Daniel, additional, Zon, Rebecca L., additional, Storm, Kelsie, additional, Mazur-Popinska, Magdalena, additional, Andolina, Laura, additional, Bubala, Halina, additional, Golebiowska, Sydonia, additional, Higman, Meghan A., additional, Kalwak, Krzysztof, additional, Kurre, Peter, additional, Matysiak, Michal, additional, Niewiadomska, Edyta, additional, Pels, Salley, additional, Petruzzi, Mary Jane, additional, Pobudejska-Pieniazek, Aneta, additional, Szczepanski, Tomasz, additional, Fleming, Mark D., additional, Gazda, Hanna T., additional, and Agarwal, Suneet, additional

Published
2014
Full Text
View/download PDF

23. SETD2alterations impair DNA damage recognition and lead to resistance to chemotherapy in leukemia

Author

Mar, Brenton G., Chu, S. Haihua, Kahn, Josephine D., Krivtsov, Andrei V., Koche, Richard, Castellano, Cecilia A., Kotlier, Jacob L., Zon, Rebecca L., McConkey, Marie E., Chabon, Jonathan, Chappell, Ryan, Grauman, Peter V., Hsieh, James J., Armstrong, Scott A., and Ebert, Benjamin L.

Abstract

Mutations in SETD2,encoding the histone 3 lysine 36 trimethyltransferase, are enriched in relapsed acute lymphoblastic leukemia and MLL-rearranged acute leukemia. We investigated the impact of SETD2mutations on chemotherapy sensitivity in isogenic leukemia cell lines and in murine leukemia generated from a conditional knockout of Setd2. SETD2mutations led to resistance to DNA-damaging agents, cytarabine, 6-thioguanine, doxorubicin, and etoposide, but not to a non–DNA damaging agent, l-asparaginase. H3K36me3 localizes components of the DNA damage response (DDR) pathway and SETD2mutation impaired DDR, blunting apoptosis induced by cytotoxic chemotherapy. Consistent with local recruitment of DDR, genomic regions with higher H3K36me3 had a lower mutation rate, which was increased with SETD2 mutation. Heterozygous conditional inactivation of Setd2in a murine model decreased the latency of MLL-AF9–induced leukemia and caused resistance to cytarabine treatment in vivo, whereas homozygous loss delayed leukemia formation. Treatment with JIB-04, an inhibitor of the H3K9/36me3 demethylase KDM4A, restored H3K36me3 levels and sensitivity to cytarabine. These findings establish SETD2alteration as a mechanism of resistance to DNA-damaging chemotherapy, consistent with a local loss of DDR, and identify a potential therapeutic strategy to target SETD2-mutant leukemias.

Published
2017
Full Text
View/download PDF

24. Pearson Marrow Pancreas Syndrome In a Cohort Of Diamond Blackfan Anemia Patients

Author

Gagne, Katelyn E, primary, Ghazvinian, Roxanne, additional, Yuan, Daniel, additional, Zon, Rebecca L., additional, Storm, Kelsie, additional, Mazur-Popinska, Magdalena, additional, Andolina, Laura, additional, Bubala, Halina, additional, Golebiowska, Sydonia, additional, Higman, Meghan A., additional, Kalwak, Krzysztof, additional, Kurre, Peter, additional, Matysiak, Michal, additional, Niewiadomska, Edyta, additional, Pels, Salley, additional, Petruzzi, Mary Jane, additional, Pobudejska-Pieniazek, Aneta, additional, Szczepanski, Tomasz, additional, Fleming, Mark D, additional, Gazda, Hanna T., additional, and Agarwal, Suneet, additional

Published
2013
Full Text
View/download PDF

25. Induced Pluripotent Stem Cells with a Mitochondrial DNA Deletion

Author

Cherry, Anne B. C., primary, Gagne, Katelyn E., additional, Mcloughlin, Erin M., additional, Baccei, Anna, additional, Gorman, Bryan, additional, Hartung, Odelya, additional, Miller, Justine D., additional, Zhang, Jin, additional, Zon, Rebecca L., additional, Ince, Tan A., additional, Neufeld, Ellis J., additional, Lerou, Paul H., additional, Fleming, Mark D., additional, Daley, George Q., additional, and Agarwal, Suneet, additional

Published
2013
Full Text
View/download PDF

26. Derivation of Disease-Free Induced Pluripotent Stem Cells From Patients with Pearson Marrow Pancreas Syndrome

Author

Agarwal, Suneet, primary, Cherry, Anne B.C., additional, McLoughlin, Erin M., additional, Lerou, Paul H., additional, Miller, Justine D., additional, Huo, Hongguang, additional, Hartung, Odelya, additional, Zon, Rebecca L., additional, Fleming, Mark D., additional, Ince, Tan A., additional, Neufeld, Ellis J., additional, and Daley, George Q., additional

Published
2010
Full Text
View/download PDF

27. SETD2Heterozygous Loss in Leukemia Leads to Chemotherapy Resistance through Attenuation of the DNA Damage Response

Author

Mar, Brenton G., Kahn, Josephine, Zon, Rebecca L, Grauman, Peter V, Boettger, Kevin, Chu, Scott Haihua, Armstrong, Scott A., and Ebert, Benjamin L.

Abstract

Relapsed leukemia is chemotherapy resistant and survival is poor. We recently found that mutations in epigenetic regulators are enriched in relapsed pediatric B-cell acute lymphoblastic leukemia (B-ALL), suggesting that they are associated with clonal survival and chemotherapy resistance. The mutations included loss of function mutations in the epigenetic regulator SETD2,which had not before been described in B-ALL. SETD2is the only known mammalian Histone 3 Lysine 36 (H3K36) trimethyltransferase and one or two copy loss leads to a global decrease or elimination, respectively, of its chromatin mark, H3K36me3.

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results